Release Date: March 30, 2007

Valid Through: March 29, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following original interactive case study:

Review of the Literature Regarding Treatment for Head and Neck Cancer: Six Articles with the Most Clinical Significance Published in the Last Two Years

Marshall R. Posner, MD, Medical Director, Head and Neck Oncology Program, Dana-Farber Cancer Institute

With Comments by David Raben, MD, University of Colorado Health Sciences Center

Dr. Marshall Posner is the Medical Director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute, one of the first multi-disciplinary head and neck cancer programs established in this country. Dr. Posner graduated in 1971 from Yale University and received his MD from Tufts University School of Medicine in 1975. He completed a residency in Internal Medicine at Boston City Hospital in 1978 and became a fellow in Medical Oncology at the Dana-Farber Cancer Institute. He completed his fellowship in 1981 and became an Instructor in Medicine. He was a member of the multi-disciplinary head and neck clinic at the Dana-Farber Cancer Institute from 1979-1983 and a member of the Division of Tumor Immunology. In 1983 Dr. Posner joined the Roger Williams Cancer Center and the Brown University Medical School as an Assistant Professor where he helped develop a Phase II clinical trials program and established the Human Monoclonal Antibody Laboratory. In 1991 Dr. Posner joined the New England Deaconess Hospital and in 1994 was appointed the Medical Director of the Head and Neck Oncology Program at DFCI. He became an associate Professor of Medicine at Harvard Medical School in 1994. Dr. Posner has published over 140 peer reviewed basic laboratory and clinical studies as well as numerous reviews and abstracts in clinical research and basic laboratory studies.

David Raben, MD

David Raben, MD, is an Associate Professor and Associate Scientist in the Department of Radiation Oncology at the University Colorado Comprehensive Cancer Center, Aurora, Colorado. Dr. Raben received his medical degree from the Bowman Gray School of Medicine, Wake Forest University, Winston Salem, North Carolina, and completed his residency in Radiation Oncology at Johns Hopkins University, Baltimore, Maryland. At present he is an associate scientist and associate professor in the Department of Radiation Oncology at the University of Colorado Cancer Center. Dr. Raben has established himself in the area of translational research combining radiation with biologic agents that alter the cancer cell growth cycle to enhance the effectiveness of radiation therapy for head and neck cancer.  Dr. Raben is board certified, active member of the American College of Radiology, American Society for Therapeutic Radiology and Oncology, American Society of Clinical Oncology and the American Association of Cancer Research.  Dr. Raben serves on the Translational Research Committee of the Radiation Therapy Oncology Group, American Society for Therapeutic Radiology and Oncology (ASTRO) Educational Committee, ASCO publications committee, the Southwest Oncology Group Radiation Oncology Committee and University of Colorado Cancer Committee. He also participates in the Young Leadership committee of ASTRO. He has been a participating or lead author in 42 published articles and is an adhoc reviewer for the American Journal of Clinical Oncology, Clinical Cancer Research, International Journal of Radiation Oncology Biology Physics, British Journal of Cancer, and Head and Neck.  He is currently on the editorial board of the JCO, Signal and International Journal of Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the most clinically significant published articles from the last 2 years regarding the treatment of head and neck cancer (HNC)
• Evaluate the pathologic predictors of poor prognosis in completely resected HNC
• Consider the chemotherapeutic drug options to use with radiotherapy in the post-operative setting
• Consider Phase III data and side effect profile of emerging biologic therapy in combination with radiation therapy for locally advanced HNC

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb Company.